Archive for the ‘oncology retractions’ Category
A cancer researcher has earned seven more retractions following an investigation into his work by his former employer, MD Anderson Cancer Center in Texas, bringing his total to 18 retractions.
All of the new retraction notices, issued by The Journal of Biological Chemistry (JBC), stem from image-related issues. The now-retired Aggarwal has seven papers that have each been cited at least 1,000 times, and in 2015, he was on Thomson Reuters Web of Science’s list of The World’s Most Influential Scientific Minds. With these new notices, he also has made it to our leaderboard of individual researchers who’ve racked up the most retractions.
An MD Anderson spokesperson sent us this statement: Read the rest of this entry »
The moves against the researcher, Thorsten Hagemann, come after investigations by the General Medical Council, akin to a U.S. state medical board, and Hagemann’s former institution, Queen Mary University of London (QMUL), turned up evidence of misconduct. In June, we reported on the retraction of a meeting abstract in The Journal of Pathology and the corrigendum of a Nature paper by Hagemann following the inquiry at QMUL.
Since April, the Romanian Journal of Internal Medicine (RJIM) retracted nine papers (eight for plagiarism, one for duplication); four of these were co-authored by Manole Cojocaru, a researcher at the Titu Maiorescu University (TMU) in Bucharest, Romania. Subsequently, the journal has banned Cojocaru from submitting manuscripts, and has also informed the ethics committee at his institution.
So from time to time we’ll compile a list of retractions that appeared relatively straightforward, just for record-keeping purposes.
Often, these seemingly straightforward retractions involve duplications, in which authors — accidentally or on purpose — republish their own work elsewhere.
Sometimes journals and authors blame this event on “poor communication,” our first example notes:
A JAMA journal has quickly issued a correction for a 2016 paper after the author failed to mention several relevant conflicts of interest. Normally, we’d see this as a run-of-the-mill correction notice, but since we reported last week that a journal retracted a paper for omitting pharma funding, we got to wondering: Is failure to disclose a conflict of interest a retractable offense?
Guidelines from the Committee on Publication Ethics (COPE) do say that retractions are used for “failure to disclose a major competing interest likely to influence interpretations or recommendations.” But most of the time when we see corrections to the literature for such omissions, they’re corrections, not retractions.
On Friday, JAMA Ophthalmology issued a correction notice for an invited commentary published in April, which addressed two papers in the journal about melanoma of the eye (uveal melanoma). However, the original commentary failed to note that author Arun D. Singh at the Cleveland Clinic had some relevant conflicts to mention, as the notice explains: Read the rest of this entry »
For one, the authors didn’t actually collect the data they claim to in the title of the paper, which reported on methods to screen patients for recurrence of lung cancer. The authors included data from positron emission tomography/computed tomography (PET/CT), collected from 2003 to 2007 — but their institution didn’t have a PET/CT scanner until 2009. Instead, the authors had mistakenly reported the results of PET scans alone, which may not find tumors as effectively as PET/CT.
Here’s the retraction notice in Medicine, which explains the nature of the error in more detail. (Note: One of the authors supplied some missing text, in brackets.)
When authors get new data that revise a previous report, what should they do?
In the case of a 2015 lung cancer drug study in the New England Journal of Medicine (NEJM), the journal published a letter to the editor with the updated findings.
Shortly after the paper was published, a pharmaceutical company released new data showing the drug wasn’t quite as effective as it had seemed. Once the authors included the new data in their analysis, they adjusted their original response rate of 59% — hailed as one of a few “encouraging results” in an NEJM editorial at the time of publication — to 45%, as they write in the letter. One of the authors told us they published the 2015 paper using less “mature” data because the drug’s benefits appeared so promising, raising questions about when to publish “exciting but still evolving data.”
It’s not a correction, as the original paper has not been changed; it doesn’t even contain a flag that it’s been updated. But among the online letters about the paper is one from the authors, “Update to Rociletinib Data with the RECIST Confirmed Response Rate,” which provides the new data and backstory:
One paper examined whether the results of CT scans could be used to stage patients with uterine carcinoma; the other considered whether CT scans could be used to predict overall survival in uterine carcinoma. Both papers — by researchers at the Memorial Sloan Kettering Cancer Center — used data from the same 193 women. After they appeared in in different journals, the editors considered whether they were redundant — a quality that can spell retraction for a paper.
The editors explain why they decided the papers were unique in a brief commentary — a non-retraction notice, if you will — published in
a third journal, Abdominal Radiology:
Here’s the latest one we’ve picked up: Lung Cancer has retracted a 2014 paper on the genetics of tumors after concluding the authors cribbed a figure that had appeared in a 2005 feature story in Science.
The paper, “ß-elemene against human lung cancer via up-regulation of P53 protein expression to promote the release of exosome,” drew attention on PubPeer last September from a reader who noticed striking similarities between one of the images the authors used and a figure in the Science piece (subscription required). According to the PubPeer commenter: Read the rest of this entry »
The Oncologist has tagged three review papers that share a first author with an expression of concern. The three papers, which have together been cited more than 1,000 times, focus on HER2, a gene that can contribute to breast cancer.
Though the papers contain errors, the conclusions — about how the HER2 gene serves as a predictive factor for breast cancer, and a target for therapies — remain unchanged, according to the EOC. The editor of the journal notes that the conclusions of the papers have been confirmed by other publications. Two of the papers are more than 10 years old, and today many patients continue to be treated with medications that target HER2, such as Herceptin.
Here’s the expression of concern: